Select Bibliography

 Search for any words:
Excel csv Word PDF RIS
  Filter by any of these (after searching):
      
Year
      
PubType
Primary
Endpoint
      
Analysis
      
Committee
      
Program
      
Meeting
      
Funding
                            

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 852 items

Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance)    QxMD    Google Scholar
,  ,  ... -    -  J. Clin. Oncol   -  2014    
Manuscript -  Primary -  Primary -  Breast -  CALGB-40302